CRISPR Therapeutics AG (CRSP): Results of Operations and Financial Condition
CRISPR Therapeutics AG (CRSP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results ZUG, Switzerland and BOSTON, August 3, 2026 – CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. " The second q
How this was made
The 30-second read
Why it matters
The most tradable elements are the pediatric FDA approval for CASGEVY (expanding eligible patients) and the initiation/clearance of additional in vivo programs (increasing probability of future value inflection points).
Market read
Traders can reassess CRSP’s near-term commercial trajectory (pediatric label expansion) and near-to-mid-term pipeline de-risking (new Phase 1 starts and IND clearance) based on this primary filing.
What to watch
Key swing factors for valuation are durability of CASGEVY effects, reimbursement access execution, and the pace of Phase 1/1b readouts for CTX340/CTX460 and CTX310, none of which are quantified here.
CRISPR Therapeutics reported second quarter 2026 results with CASGEVY revenue of $76 million, up 78% quarter-over-quarter and 151% year-over-year, while net loss narrowed to $91.2 million.
CASGEVY revenue growth accelerated and operating expense categories declined year-over-year, while the company expanded several clinical programs and ended the quarter with $2,364.4 million of cash, cash equivalents, and marketable securities. The company remained loss-making and reported no financial guidance.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| CASGEVY revenueother | $76 million | 78% growth quarter-over-quarter | 151% growth year-over-year |
| R&D expensesGAAP | $67.2 million | – | – |
| Acquired in-process R&D expensesGAAP | $2.5 million | – | – |
| General and administrative expensesGAAP | $17.6 million | – | – |
| Collaboration expense, netGAAP | $40.3 million | – | – |
| Net lossGAAP | $91.2 million | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| CASGEVYCASGEVY momentum continued to build, including FDA approval for children 2 years of age and older with SCD or TDT. | $76 million | 78% growth quarter-over-quarter | 151% growth year-over-year |
second half of 2026 outlook
- NoteThe Company expects to provide a Phase 1b clinical update for CTX310 in the second half of 2026.
- NoteThe Company expects to provide an update for CTX611 in the second half of 2026.
- NoteThe Company expects to provide further updates on the zugo-cel autoimmune clinical program in the second half of 2026.
- NoteUpdates for the Phase 1/2 clinical trial of zugo-cel in B-cell malignancies are anticipated in the second half of 2026.
What drove it
- CASGEVY generated second quarter 2026 revenue of $76 million, representing 78% growth quarter-over-quarter and 151% growth year-over-year.
- The U.S. FDA approved CASGEVY in children 2 years of age and older with SCD or TDT.
- Vertex secured reimbursement for CASGEVY for eligible patients 12 years and older with SCD or TDT in Germany.
- CRISPR Therapeutics initiated Phase 1 clinical trials for CTX340 for refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency.
- The decrease in collaboration expense was primarily attributable to an increase in the Company's share of CASGEVY revenue.
Concerns
- Net loss was $91.2 million for the second quarter of 2026.
- Efforts remain underway with government and reimbursement authorities globally to ensure sustainable access for eligible patients.
- The increase in cash was offset by operating expenses.
- The company reported no financial revenue, expense, margin, or tax-rate guidance.
What to watch
- Clinical update of the ongoing Phase 1a trial of CTX310 at the European Society of Cardiology Congress 2026 on August 28 at 4:30 p.m. CET.
- Phase 1b clinical update for CTX310 expected in the second half of 2026.
- Update for CTX611 expected in the second half of 2026.
- Further zugo-cel autoimmune-program updates and B-cell malignancy trial updates anticipated in the second half of 2026.
- An Lp(a) program update is anticipated in 2026.
- An update on up to two additional siRNA targets is expected in 2026.
Balance sheet and cash flow
- Cash, cash equivalents, and marketable securities were $2,364.4 million as of June 30, 2026, compared to $1,975.8 million as of December 31, 2025.
- The increase in cash was primarily driven by net proceeds of $585.4 million from the issuance of convertible senior notes in March 2026, offset by operating expenses.
Analysis
CASGEVY was the central commercial driver in the second quarter. The therapy generated $76 million of revenue, with 78% growth quarter-over-quarter and 151% growth year-over-year. The FDA approval for children 2 years of age and older with SCD or TDT expands the eligible population, while reimbursement was secured in Germany for eligible patients 12 years and older with SCD or TDT.
The reported expense base declined across R&D, general and administrative expense, and collaboration expense, net, compared with the second quarter of 2025. Acquired in-process R&D expense also declined substantially from the prior-year period, when costs were related to entering the Sirius Agreement. Net loss narrowed to $91.2 million from a net loss of $208.5 million in the second quarter of 2025.
Liquidity increased to $2,364.4 million of cash, cash equivalents, and marketable securities as of June 30, 2026, compared with $1,975.8 million as of December 31, 2025. The company attributed the increase primarily to net proceeds of $585.4 million from convertible senior notes issued in March 2026, offset by operating expenses. No capital-return activity was reported.
Portfolio execution extended beyond CASGEVY. The company initiated Phase 1 trials for CTX340 and CTX460, continued CTX310 development, and advanced CTX611 and zugo-cel across multiple clinical settings. The second-half agenda includes CTX310, CTX611, zugo-cel, and immuno-oncology updates, alongside an anticipated Lp(a) program update. The release did not provide financial revenue, expense, margin, or tax-rate guidance.
Management, verbatim
The second quarter reflected strong execution across CRISPR Therapeutics' portfolio and platform.
Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics
CASGEVY's momentum continued to build, highlighted by the FDA's approval for children as young as 2 years old, while we expanded our in vivo pipeline with the initiation of Phase 1 clinical trials for CTX340 for refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency. We enter the second half of 2026 well positioned, with a number of important milestones ahead across our pipeline.
Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics
Not in the filing
stated, not guessed- Total company revenue
- Total revenue prior-year comparison
- Total revenue prior-quarter comparison
- Gross profit
- Gross margin
- Operating income or loss
- Operating expenses total
- Income tax expense or benefit
- Tax rate
- GAAP EPS
- Non-GAAP EPS
- Non-GAAP financial metrics
- Operating cash flow
- Free cash flow
- Debt balance as of June 30, 2026
- Share repurchases
- Dividends
- Financial revenue guidance
- Gross-margin guidance
- Operating-expense guidance
- Tax-rate guidance
- Prior outlook or prior-guidance comparison
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
CRISPR Therapeutics filed an SEC Form 8-K (Item 2.02) with an attached exhibit summarizing Q2 2026 financial results and pipeline/business updates.
Ticker impact
CRISPR Therapeutics reports Q2 2026 results and highlights FDA approval of CASGEVY for children as young as 2, plus new Phase 1 starts for CTX340 and CTX460.
Likely positive near-term bias as traders price expanded addressable market and de-risked regulatory progress, with follow-through dependent on subsequent commercial uptake and later clinical readouts.
The article is a primary SEC 8-K business update with specific, time-stamped events: CASGEVY pediatric FDA approval and initiation/clearance of multiple in vivo programs. However, it does not provide full financial guidance or detailed margin/cash-flow metrics in the excerpt, limiting precision on magnitude.
Market effects
Reinforces momentum in gene-edited cell therapy and in vivo delivery platforms, potentially supporting sentiment across rare-disease and gene-therapy peers.
US FDA pediatric expansion can lift global expectations for commercialization timelines and reimbursement negotiations.
Multiple-country approvals and submissions (Saudi Arabia, UK, Germany reimbursement) suggest broader international scaling beyond the US.
Counterpoint
Revenue growth and approvals may already be partially anticipated; without detailed cash burn, guidance, or durability/clinical endpoints, the market may fade the initial enthusiasm.
Key entities
- issuerCRISPR Therapeutics AG
Subject of the SEC 8-K business update and Q2 2026 financial results.
- productCASGEVY (exagamglogene autotemcel)
Gene-edited cell therapy; FDA approved for children as young as 2 years old with SCD or TDT.
- pipeline_programCTX340
Investigational therapy targeting angiotensinogen (AGT); IND clearance and Phase 1 trial initiated for refractory hypertension.
- pipeline_programCTX460
Investigational therapy targeting SERPINA1 for alpha-1 antitrypsin deficiency; Phase 1 trial initiated.
